Exploring antifungal activities of Rhazya stricta and Azadirachta indica leaves against human black fungus
Paper Details
Exploring antifungal activities of Rhazya stricta and Azadirachta indica leaves against human black fungus
Abstract
Mucormycosis or black fungus infection originates from Mucor which belong to Mucorales order of fungi. At present mucormycosis spread vastly attacks human beings. Immunosuppressive glucocorticoid drugs are used widely in SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). These article aimed to discover antifungal therapies using medicinal plants has increased for the following reasons: 1- The richness of plant flora in Saudi Arabia and the low knowledge in the use of medicinal plants, 2- the 2030 vision of Saudi Arabia’s mutual interest in medicinal plants using Rhazya stricta and Azadirachta indica, were collected during January 2021 from saline soil, Plant Extraction using; methanol (70%), and distilled water, GC-MS analysis, then antifungal activity were examined, and observe the extraction effect on the fungus cell by Electron microscope. Results declared that the aqueous and methanolic leaf extracts of R. stricta and A. indica possess efficient antimicrobial effects against the test bacterial strains, particularly the methanolic extracts.
Ahmad A, Ahad A, Rao AQ, Husnain T. 2015. Molecular Docking Based Screening of Neem-Derived Compounds with the NS1 Protein of Influenza Virus. Bioinformation 11 (7), 359–365. DOI: 10.6026/97320630011359
Al-Harbi NA. 2017. Survey of Plant Species of Medical Importance to Treat Digestive Tract Diseases in Tabuk Region, Saudi Arabia. Journal of King Abdulaziz University 29, 51-61. https://doi.org/10.4197/Sci.29-1.6
Alzohairy MA. 2016. Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment. Evid Based Complement Alternat Med. 2016:2016:7382506. DOI: 10.1155/2016/7382506.
Aumeeruddy MZ, Mahomoodally MF. 2021. Ethnomedicinal Plants for the Management of Diabetes Worldwide: A Systematic Review. Curr. Med. Chem. 28 (23), 4670–4693. DOI: 10.2174/0929867328666210121123037
Aware CB, Patil DN, Suryawanshi SS, Mali PR, Rane MR, Gurav RG, Jadhav JP. 2022. Natural bioactive products as promising therapeutics: A review of natural product-based drug development. S. Afr. J. Bot. 151, 512–528.
Bashir AK, Abdalla AA, Hassan ES, Wasfi IA, Amiri MA, Crabb TA. 1994. Alkaloids with antimicrobial activity from the root of Rhyzya stricta Decn. growing in United Arab Emirates. Arab Gulf J. Sci. Res. 12, 119–131.
Beigomi M, Mojahed M, HeydariSadegh B, Dahmardeh N, Rouhani R, Javadian F. 2021. Evaluation of Antimicrobial Activity of Rhazya stricta (Apocynaceae) Extract Prepared with Different Solvents on Staphylococcus aureus (Staphylococcaceae) Isolated from Humans. International Journal of Advanced Biological and Biomedical Research 9(3), 241-253.
Bourgonje AR, Abdulle AE, Timens W. 2020. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J. Pathol. 251, 228–248. DOI: 10.1002/path.5471.
Caetano LA, Faria T, Springer J, Loeffler J, Viegas C. 2018. Antifungal-resistant Mucorales in different indoor environments. Mycology 10, 75–83. DOI: 10.1080/21501203.2018.1551251.
Chakrabarti A, Dhaliwal M. 2013. Epidemiology of mucormycosis in India. Curr Fungal Infect Rep. 7, 287–92.
Chandley P, Subba P, Rohatgi S. 2022. COVID-19-Associated Mucormycosis: A Matter of Concern Amid the SARS-CoV-2 Pandemic. Vaccines (Basel). 10(8), 1266-73.
Charmaine Lloyd AC, Menon T, Umamaheshwari K. 2005. Anticandidal activity of Azadirachta indica. Research Paper 37(6), 386- 389.
Chaudhary S, Kanwar RK, Sehgal A, Cahill DM, Barrow CJ, Sehgal R. 2017. Progress on Azadirachta indica Based Biopesticides in Replacing Synthetic Toxic Pesticides. Front. Plant Sci. 8, 610.
Choudhary N, Jain A, Soni R, Gahlot N. 2021. Mucormycosis: A deadly black fungus infection among COVID-19 patients in India. Clin Epidemiol Glob Health. 100900. DOI: 10.1016/j.cegh.2021.100900
Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. 2015. Mechanisms of Antifungal Drug Resistance. Cold Spring Harb. Perspect. Med. 5, a019752. DOI: 10.1101/cshperspect.a019752
El-Shora HM, Abd El-Gawad AM. 2014. Evaluation of allelopathic potential of Rumex dentatus root extract and allele chemicals on Cicer arietinum. J. Stress Physiol. Biochem. 10, 177-180.
Emad MA, Gamal EE. 2013. Screening for antimicrobial activity of some plants from Saudi folk medicine. Global J. Res. Med. Plants & Indigen. Med. 2, 189–197.
Fazeli-Nasab B, Sayyed R Z, Sobhanizadeh A. 2021. In Silico Molecular Docking Analysis of αPinene: An Antioxidant and Anticancer Drug Obtained from Myrtus communis. International Journal of Cancer Management 14(2), e89116. https://doi.org/10.5812/ijcm.89116
Gao Z, Liu Y, Wang X, Wei X, Han J. 2019. DNA mini-barcoding: A derived barcoding method for herbal molecular identification. Front. Plant Sci. 10, 987.
Gilani SA, Kikuchi A, Shinwari ZK, Khattak ZI, Watanab KN. 2006. Phytochemical, pharmacologicaland ethnobotanical studies of Rhazya stricta Decne. Phytotherapy Research 21, 301-307
Gupta SC, Prasad S, Tyagi AK, Kunnumakkara AB, Aggarwal BB. 2017. Neem (Azadirachta indica): An Indian Traditional Panacea with Modern Molecular Basis. Phytomedicine 34, 14–20. DOI:10.1016/j.phymed.2017.07.001
Hernández JL, Buckley CJ. 2021. Mucormycosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing.
Hussain S, Riad A, Singh A, Klugarová J, Antony B, Banna H. 2021. Global prevalence of COVID-19-associated mucormycosis (CAM): living systematic review and meta-analysis. J Fungi 7, 985. DOI: 10.3390/jof7110985.
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. 2012. Pathogenesis of mucormycosis. Clin Infect Dis. 54(Suppl 1), S16–22.
Iman M, Taheri M, Bahari Z. 2021. The Anti-cancer Properties of Neem (Azadirachta indica) through its Antioxidant Activity in the Liver; its Pharmaceutics and Toxic Dosage Forms; a Literature Review. J. Complement Integr. Med. 19(2), 203-211. DOI: 10.1515/jcim-2021-0009.
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Chen SCA. 2019a. Contemporary Management and Clinical Outcomes of Mucormycosis: A Systematic Review and Meta-Analysis of Case Reports. Int. J. Antimicrob. Agents 53, 589–597. DOI: 10.1016/j.ijantimicag.2019.01.002
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM. 2019b. The Epidemiology and Clinical Manifestations of Mucormycosis: A Systematic Review and Meta-Analysis of Case Reports. Clin. Microbiol. Infect. 25, 26–34. DOI: 10.1016/J.CMI.2018.07.011
Jităreanu A, Trifan A, Mădălina V, Ioana-Cezara C, Mârțu I, Luminița A. 2023. Current Trends in Toxicity Assessment of Herbal Medicines: A Narrative Review. Processes 11, 1-39.
Kasimadom K. 2021. Ayurveda approach to mucormycosis and other fungal infections: A comprehensive review. Journal of Indian System of Medicine 9(4), 216-222.
Khan R, Baeshen MN, Saini KS, Bora RS, Al-Hejin AM, Baeshen NA. 2016. Antibacterial activities of Rhazya stricta leaf extracts against multidrugresistant human pathogens. Biotechnology & Biotechnological Equipment 30(5), 1016-1025. https://doi.org/10.1080/13102818.2 016.1209087
Khan S, Khan GM. 2007. In vitro antifungal activity of Rhazya stricta. Pak. J. Pharm. Sci. 20, 279–284.
Kilani-Morakchi S, Morakchi-Goudjil H, Sifi K. 2021. Azadirachtin-Based Insecticide: Overview, Risk Assessments, and Future Directions. Front. Agron. 3, 676208. https://doi.org/10.3389/fagro.2021.676208
Lamoth F, Lewis R E, Kontoyiannis DP. 2022. Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective. Clin. Infect. Dis. 5, 27. DOI: 10.1093/cid/ciab1070
Lax C, Navarro-Mendoza MI, Pérez-Arques C, Navarro E, Nicolás FE, Garre V. 2021. Stable and Reproducible Homologous Recombination Enables CRISPR-Based Engineering in the Fungus Rhizopus microsporus. Cell Rep. Methods 1, 100124. DOI: 10.1016/j.crmeth.2021.100124
Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P. 2021. Mucormycosis: an opportunistic pathogen during COVID-19. Environ Res. 2021; 201. DOI: 10.1016/j.envres.2021.111643.
Martinelli L, Kopilaš V, Vidmar M, Heavin C, Machado H, Todorović Z, Buzas N, Pot M, Prainsack B, Gajović S. 2021. Face Masks During the COVID-19 Pandemic: A Simple Protection Tool with Many Meanings. Front. Public Health 8, 1-12.
Mehta S, Pandey A. 2020. Rhino-orbital mucormycosis associated with COVID-19. Cureus 12, e10726.
Mohamed M, Bander A, Tarombera M, Mohamed F, Roqayah H, Alaa A, Elsharkawy M. 2023. The Antibacterial Activity of Rhazya stricta Extracts against Klebsiella pneumoniae Isolated from Some Soil Invertebrates at High Altitudes. Molecules 28(8), 3613-20.
Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. 2007. Rhinocerebral mucormycosis: the disease spectrum in 27 patients. Mycoses 50, 290–296. DOI 10.1111/j.1439-0507.2007.01364.x.
Mousavi B, Costa JM, Arne P, Guillot J, Chermette R, Botterel F, Dannaoui E. 2018. Occurrence and species distribution of pathogenic Mucorales in unselected soil samples from France. Med. Mycol. 56, 315–321. DOI: 10.1093/mmy/myx051.
Mukne A, Momin M, Betkar P, Joshi V. 2022. Standardization of herbal biomolecules. In Herbal Biomolecules in Healthcare Applications, 1st ed.; Mandal SC, Nayak AK, Dhara AK, Eds.; Elsevier Academic Press: Cambridge, MA, USA. pp.643–667.
Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. 2021. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: india versus the rest of the world. Mycopathologia 186, 739–754. DOI: 10.1007/s11046-021-00584-8.
Pak J, Tucci VT, Vincent AL, Sandin RL, Greene JN. 2008. Mucormycosis in immunochallenged patients. J Emerg Trauma Shock 1(2), 106–113. DOI: 10.4103/0974-2700.42203.
Pasquoto-Stigliani T, Campos EVR, Oliveira JL, Silva CMG, Bilesky-José N, Guilger M. 2017. Nanocapsules Containing Neem (Azadirachta indica) Oil: Development, Characterization, and Toxicity Evaluation. Sci. Rep. 7 (1), 5929.
Patil SM, Shirahatti PS, Ramu R. 2021. Azadirachta indica A. Juss (Neem) against Diabetes Mellitus: a Critical Review on its Phytochemistry, Pharmacology, and Toxicology. J. Pharm. Pharmacol. 74(5), 681-710. DOI:10.1093/jpp/rgab098
Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J. 2019. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 57, 395–402.
Rapidis AD. 2009. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon. Clin Microbiol Infect. 15(Suppl. 5), 98–102. DOI: 10.1111/j.1469-0691.2009.02989.x.
Reid G, Lynch JP, 3rd, Fishbein MC, Clark NM. 2020. Mucormycosis. Semin Respir Crit Care Med. 41(1), 99-114. DOI: 10.1055/s-0039-3401992.
Revie NM, Iyer KR, Robbins N, Cowen LE. 2018. Antifungal Drug Resistance: Evolution, Mechanisms and Impact. Curr. Opin. Microbiol. 45, 70–76. DOI: 10.1016/j.mib.2018.02.005
Ribeiro-Santos R, Andrade M, Sanches-Silva A, de Melo NR. 2018. Essential oils for food application: natural substances with established biological activities. Food and Bioprocess Technology 11(1), 43-71.
Richardson M. 2009. The ecology of the Zygomycetes and impact on environmental exposure. Clin. Microbiol. Infect. 15, 2–9. DOI: 10.1111/j.1469-0691.2009.02972.x.
Richardson MD. 2020. Rautemaa-Richardson R. Biotic Environments Supporting the Persistence of Clinically Relevant Mucormycetes. J. Fungi. 6, 4. DOI: 10.3390/jof6010004.
Riley TT, Muzny CA, Swiatlo E, Legendre DP. 2016. Breaking the mold: A review of mucormycosis and current pharmacological treatment options. Ann Pharmacother. 50, 747–57.
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL. 2005. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 41, 634–53.
Ruhnke M, Groll AH, Mayser P, Ullmann AJ, Mendling W, Hof H. 2015. Estimated burden of fungal infections in Germany. Mycoses 58, 22–8.
Saegeman V, Maertens J, Ectors N, Meersseman W, Lagrou K. 2010. Epidemiology of mucormycosis: Review of 18 cases in a tertiary care hospital. Med Mycol. 48, 45–54.
Sarkar S, Gokhale T, Choudhury SS, Deb AK. 2021. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 69, 1002–1004. DOI: 10.4103/ijo.IJO_3763_20.
Shang Y, Pan C, Yang X. 2020. Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. Ann. Intensive Care. 10, 73. DOI: 10.1186/S13613-020-00689-1.
Sharma A, Goel A. 2022. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol (Praha) 26, 1-25.
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. 2021. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J Laryngol Otol. 135, 442–7.
Shehzad A, Qureshi M, Jabeen S, Ahmad R, Alabdalall AH, Aljafary MA, Al-Suhaimi E. 2018. Synthesis, characterization and antibacterial activity of silver nanoparticles using Rhazya stricta. PeerJ 6, e6086.
Singh AK, Singh R, Joshi SR, Misra A. 2021. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 15(4), 102146. DOI: 10.1016/j.dsx.2021.05.019.
Skiada A, Pavleas I, Drogari-Apiranthitou M. 2020. Epidemiology and diagnosis of mucormycosis: An update. J Fungi (Basel) 6, 265.
Soare AY, Watkins TN, Bruno VM. 2020. Understanding Mucormycoses in the Age of “Omics.” Front. Genet. 11, 699. DOI: 10.3389/fgene.2020.00699
Song P, Li W, Xie J, Hou Y, You C. 2020. Cytokine storm induced by SARS-CoV-2. Clinica Chimica Acta. 509, 280–287. DOI: 10.1016/j.cca.2020.06.017.
Spellberg B, Edwards Jr. J, Ibrahim A. 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol. Rev. 18(3), 556–569. DOI: 10.1128/CMR.18.3.556-569.2005.
Tnah L, Lee S, Tan A, Lee C, Ng K, Ng C, Farhanah ZN. 2019. DNA barcode database of common herbal plants in the tropics: A resource for herbal product authentication. Food Control 95, 318–326.
Vasudevan B, Hazra N, Shijith K, Neema Sh, Vendhan S. 2021. Mucormycosis: The Scathing Invader. Indian J. Dermatol. 66(4), 393–400. DOI: 10.4103/ijd.ijd_477_21
Wu H-Y, Shaw P-C. 2022. Strategies for molecular authentication of herbal products: From experimental design to data analysis. Chin. Med. 17, 38.
Wylie MR. Merrell DS. 2022. The Antimicrobial Potential of the Neem Tree Azadirachta indica. Front Pharmacol. 13, 891535.
Yarmohammadi F, Mehri S, Najafi N, Salar Amoli S, Hosseinzadeh H. 2021. The Protective Effect of Azadirachta indica (Neem) against Metabolic Syndrome: A Review. Iran. J. Basic Med. Sci. 24(3), 280–292. DOI: 10.22038/ijbms.2021.48965.11218
Zain ME, Awaad AS, Al-Outhman MR, El-Meligy RM. 2012. Antimicrobial activities of Saudi Arabian desert plants. Phytopharmacol. 2, 106-113.
Zhou Q, Chen V, Shannon CP. 2020. Interferon-α2b treatment for COVID-19. Front. Immunol. 11, 1061. DOI: 10.3389/fimmu.2020.01061.
Zohra M, Fawzia A. 2013. Fungitoxic effect of natural extracts on mycelial growth, spore germination and aflatoxin B1production of Aspergillus flavus. AJCS 7(3), 293-298.
Nagwa T. Elsharawy, Afra Mohammed Baghdadi, Amna A. Saddiq, Ravi Naidu (2024), Exploring antifungal activities of Rhazya stricta and Azadirachta indica leaves against human black fungus; JBES, V24, N5, May, P106-118
https://innspub.net/exploring-antifungal-activities-of-rhazya-stricta-and-azadirachta-indica-leaves-against-human-black-fungus/
Copyright © 2024
By Authors and International
Network for Natural Sciences
(INNSPUB) https://innspub.net
This article is published under the terms of the
Creative Commons Attribution License 4.0